Corcept's ROSELLA Phase 3 posts results for relacorilant plus nab-paclitaxel in ovarian cancerSep 25Trial updateCorcept Therapeuticspaclitaxel
Corcept names Justin Gunn to succeed retiring endocrinology president Sean MaduckSep 23PeopleCorcept Therapeutics
Corcept raises 2026 revenue guidance to $1.1-$1.2 billion after Lifyorli launch quarterJul 29Quarterly updateCorcept Therapeuticsmifepristone
Sign inSign in